Imunon, Inc.
IMNN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IMNN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMNN
Imunon, Inc. is a clinical-stage biopharmaceutical company focused on developing DNA-based immunotherapy and vaccine technologies, with its lead candidate IMNN-001 in a Phase 3 registrational trial for advanced ovarian cancer.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials · 1 catalyst for Imunon, Inc..
Imunon, Inc. is a clinical-stage biopharmaceutical company focused on developing DNA-based immunotherapy and vaccine technologies, with its lead candidate IMNN-001 in a Phase 3 registrational trial for advanced ovarian cancer.
- Lead candidate IMNN-001 is being evaluated in a Phase 3 registrational trial for advanced ovarian cancer [sec_mda · as of 2026-03-31].
- Cash and equivalents were $6.9 million as of 2026-06-30, with a net loss of $2.8 million for the quarter [sec].
- The company has an accumulated deficit of $421 million as of December 31, 2025 [sec_mda · as of 2026-03-31].
- Imunon does not expect to generate product revenue in the next several years, if at all [sec_mda · as of 2026-08-11].
- The company has a history of significant losses and negative cash flows from operations, relying on equity sales, credit facilities, and licensing agreements for financing [sec_mda · as of 2026-08-11].
What works
- Imunon has advanced IMNN-001 into a Phase 3 registrational trial, a key milestone that could lead to regulatory submission if successful [sec_mda · as of 2026-03-31].
- The company maintains a diversified pipeline strategy, pursuing research and development across multiple drug candidates and indications to mitigate risk [sec_mda · as of 2026-08-11].
- Imunon has historically secured financing through equity sales, credit facilities, and licensing agreements, demonstrating some ability to access capital [sec_mda · as of 2026-08-11].
What to weigh
- Imunon has an accumulated deficit of $421 million and no product revenue, with no expectation of revenue in the foreseeable future [sec_mda · as of 2026-03-31].
- The company's cash position of $6.9 million as of 2026-06-30 is limited, and it will require significant additional capital to complete development and clinical trials [sec_mda · as of 2026-08-11].
- There is substantial uncertainty regarding the timing and outcome of clinical results, which could disproportionately impact the company's financial condition and market value [sec_mda · as of 2026-05-12].
- The company has expressed substantial doubt about its ability to continue as a going concern, with financial statements not including adjustments if it cannot [sec_mda · as of 2026-05-12].
From the filings
Quoted directly from source documents.
Imunon has incurred significant losses and has an accumulated deficit of $421 million.
“we incurred a net loss of $14.5 million. We have incurred approximately $421 million of cumulative net losses.”
SEC MD&A · March 31, 2026
The company does not expect product revenue in the near term.
“expect to generate any revenue from product sales in the next several years, if at all.”
SEC MD&A · August 11, 2026
The company faces substantial doubt about its ability to continue as a going concern.
“The Company's financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount and classification of liabilities that may be required should the Company be unable to continue as a going concern.”
SEC MD&A · May 12, 2026
Catalyst timeline
- 2032-10-31 · Phase 3 Topline: A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combinati — Topline results from the registrational trial of IMNN-001 in advanced ovarian cancer will be a key value inflection point.
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern; financial statements may require adjustments [sec_mda · as of 2026-05-12].
- Cash runway limited — Only $6.9M cash as of 2026-06-30; needs significant additional capital for trials and operations [sec].
- No product revenue — No product revenue expected for several years; relies on external financing [sec_mda · as of 2026-08-11].
- Clinical trial risk — Phase 3 trial outcome uncertain; failure could disproportionately impact financial condition [sec_mda · as of 2026-05-12].
What to watch
- Phase 3 topline data for IMNN-001 in advanced ovarian cancer, expected by 2032-10-31 [catalyst].
- Ability to raise additional capital to fund ongoing operations and clinical development [sec_mda · as of 2026-08-11].
- Any updates on collaborative agreements or licensing deals that could provide non-dilutive funding [sec_mda · as of 2026-08-11].
- Changes in cash position and burn rate in upcoming quarterly filings [sec].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Imunon, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Imunon, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
7.4 months
D/E 2.58 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~2254d
0 buys · 5 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
17
Total value held
$1.5M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 348,330 | $1.0M |
| vanguard capital management llc | 96,112 | $283K |
| geode capital management, llc | 33,211 | $98K |
| vanguard fiduciary trust co | 13,269 | $39K |
| blackrock, inc. | 4,464 | $13K |
| wells fargo & company/mn | 3,342 | $10K |
| morgan stanley | 3,035 | $9K |
| sbi securities co., ltd. | 1,027 | $3K |
| ubs group ag | 575 | $2K |
| hrt financial lp | 12,055 | $35 |
Showing top 10 of 17 institutional holders of Imunon, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 3.6%
- Days to cover
- 0.7
- Shares short
- 142,264
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMNN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Imunon, Inc.?
Imunon, Inc. is a clinical-stage biopharmaceutical company focused on developing DNA-based immunotherapy and vaccine technologies, with its lead candidate IMNN-001 in a Phase 3 registrational trial for advanced ovarian cancer.
What is Imunon, Inc.'s next catalyst?
Imunon, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combinati" — expected October 31, 2032.
Who is the CEO of Imunon, Inc.?
Dr. Stacy R. Lindborg Ph.D. is the chief executive officer of Imunon, Inc. (IMNN).
Where is Imunon, Inc. headquartered?
Imunon, Inc. (IMNN) is headquartered in Lawrenceville, NJ, United States.
What therapeutic areas does Imunon, Inc. focus on?
Imunon, Inc. develops therapies across Oncology, Immunology, Infectious Disease, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.